On 22 May 2026, the European Medicines Agency (EMA) published an overview of invented names reviewed in April 2026 by its Name Review Group (NRG), as adopted at the Committee for Medicinal Products for Human Use (CHMP) meeting of 21 May 2026. The document lists the names considered and their outcomes, providing transparency for pharmaceutical companies and stakeholders involved in the marketing authorisation process.
The overview, produced by EMA's NRG, details the names reviewed during April 2026, including those accepted, rejected, or requiring modification. The NRG evaluates proposed invented names for medicinal products to ensure they are not misleading, do not cause confusion with existing products, and comply with regulatory requirements. This publication is part of EMA's routine transparency efforts, offering guidance to applicants on naming conventions.
No prior coverage of this specific document exists in recent records. The document serves as a reference for industry professionals preparing marketing authorisation applications, helping them avoid common pitfalls in name selection. It also informs national competent authorities about the NRG's decisions, supporting harmonised assessment across EU member states.
Stakeholders impacted include pharmaceutical companies developing new drugs, who must align their proposed names with NRG expectations to avoid delays. Regulatory consultants and legal advisors will use the overview to advise clients on naming strategies. National medicines agencies benefit from consistent evaluation criteria. Patients and healthcare professionals are indirectly affected, as clear and distinct names reduce medication errors.
The publication does not introduce new policy but reinforces existing guidelines. No immediate institutional follow-up is expected beyond the routine monthly updates from the NRG.
← Atlas › News › Health & Lifestyle